and shared learnings so far and I am sure that you all will find it an interesting read.
Anurag Mishra, General Manager India
Then in 2018…
Ever since its inception in India, Werfen has seen remarkable progress and slowly emerged as the major player in segments of hemostasis and blood gas analysis and carving out a niche in Autoimmunity segment. The sales team with their vast experience were able to expand the installed base across the country. However, as it is very commonly said “What brought you HERE’’ will not be able to ‘KEEP YOU HERE” let alone ‘TAKE YOU THERE’. And that applies very aptly to the organization in India because of a high VUCA environment. The market dynamics has been changing from quite few years now, competition was getting aggressive, more competitors were getting added, customers were becoming more demanding than ever. And it looked like these trends were here to stay. And to add to it, acquisitions of TEM and Accriva brought forward a need to getting foothold in Acute care segment, a path less familiar to the organization.
It was the time when Werfen India realized that there was the need to change the way it has been operating, in order to stay relevant. And thus, the concept of “Clinical Marketing” was introduced and two Clinical specialists were brought on board. The responsibility of Hemostasis and Acute care was given to Dr. Ajay Gandhi (MD-Pathology with more than 10 years of lab experience) and Dr. Vikas Vats (PhD. Immunology) was given responsibility of Autoimmunity segment.
And in 2019…
Ever since the introduction of “Clinical Marketing’’ function, Werfen India has been witnessing transformation in many aspects. The first and foremost being building the internal sales and product teams’ competence thus enabling them to cross “The Great Divide” between transactional selling and consultative selling. Secondly, the initiative led to change the customer perception of Werfen being a “product Selling’ to “Value and Solution Selling’’ organization. Thirdly, and probably most importantly, Werfen slowly started emerging as an institution with aim of providing clinical education and spreading awareness on key clinical and diagnostics challenges and that started fulfilling an unmet need of clinicians and laboratory professional in the country.
In 2020 when the Pandemic struck…
Nobody would have imagined what the world is going through today. Pandemic brought additional challenges to the organization with increasing relevance of hemostasis on Covid-19 patients and added to the same when the awareness around D-Dimer assay was minimal in the country. The real test of Clinical function thus began and a marathon of clinical sessions, webinars, practical problem-solving sessions, educating treating physicians and lab professions on D-Dimer interpretation in various clinical scenarios, co-ordination with national and international experts started.
Today at the far end of 2020…
Werfen India enabled by “Clinical Marketing’ function is a transformed organization now. We have had some landmark achievements – Establishing a Scientific Advisory Committee of PBM and coming out with first ever PBM recommendations in India, Starting an accredited ‘Certificate Course in PBM’ with more than 100 delegates, Initiating first ever dedicated “Autoimmunity seminar’ in India, Organizing “ILLUMINATION Series” which is a regular online event which address key hemostasis challenges. All these initiatives are being organized under the banner of ‘Werfen Academy’ which has become a Brand now and offers a definite competitive advantage to Werfen India.
Conclusions: Decision to bring clinical capability further augmented our value selling efforts, enhanced sales force effectiveness and better brand perception. It has started paying encouraging dividends in short and mid-term basis and it would continue to do even better in long term as well. This is a capability which we recommend being imbibed by all our partners in different areas and affiliates globally.



